OPTIMIZATION IN THE MANAGEMENT OF METASTATIC RENAL CELL CARCINOMA WITH IMMUNE CHECKPOINT AND ANGIOGENESIS INHIBITORS

With this doctoral project, we aim to improve the management of metastatic renal cell carcinoma, with the following work packages: 1. Optimal hour of administration of first-line ICPIs in patients affected by mRCC: morning versus afternoon. 2. Optimal treatment duration of ICPIs (two years or beyond) in patients who are responding to the therapy. 3. Optimal treatment of mRCC with bone metastases: risks and benefits of concomitant VEGFR- TKIs and denosumab. 4. Optimal treatment of mRCC with angiogenesis inhibitors and ICPIs depending on the site of metastasis. 5. Optimal treatment of metastatic papillary renal cell carcinoma according to the new WHO histologic classification. 6. Optimal management and prediction of immune related adverse events (irAEs) through the study of the impact of germline HLA promiscuity on the incidence of irAEs.